1. Home
  2. PGNY vs SUPN Comparison

PGNY vs SUPN Comparison

Compare PGNY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Progyny Inc.

PGNY

Progyny Inc.

HOLD

Current Price

$31.56

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$45.77

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGNY
SUPN
Founded
2008
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
PGNY
SUPN
Price
$31.56
$45.77
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$26.50
$61.60
AVG Volume (30 Days)
1.1M
825.5K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
14.04
N/A
EPS
0.29
N/A
Revenue
$1,288,661,000.00
$392,755,000.00
Revenue This Year
$8.87
$22.70
Revenue Next Year
$9.76
$19.14
P/E Ratio
$108.72
N/A
Revenue Growth
10.40
N/A
52 Week Low
$16.10
$38.40
52 Week High
$33.07
$59.68

Technical Indicators

Market Signals
Indicator
PGNY
SUPN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
PGNY
SUPN

About PGNY Progyny Inc.

Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: